Company Curis, Inc.

Equities

CRIS

US2312693094

Biotechnology & Medical Research

Delayed Nasdaq 01:55:49 2024-03-28 pm EDT 5-day change 1st Jan Change
10.66 USD -1.93% Intraday chart for Curis, Inc. -1.57% -16.39%

Business Summary

Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. Emavusertib, its lead clinical-stage drug candidate, is an orally available small molecule drug candidate that is designed to inhibit the Interlukin-1 receptor associated kinase 4 (IRAK4) kinase, which is an important transducer of toll-like receptor or certain interleukin receptor signaling pathways. Erivedge is an orally bioavailable small molecule, which is designed to selectively inhibit the Hedgehog signaling pathway by targeting a protein called Smoothened. Its other programs include CI-8993, Fimepinostat, CA-170 and CA-327. CI-8993 is a human IgG1 kappa monoclonal antibody directed against the VISTA protein. CA-170 is an oral small molecule drug candidate that is designed to selectively target VISTA and PDL1 immune checkpoint proteins. The Company conducts its research and development programs both internally and through strategic collaborations.

Number of employees: 49

Sales per Business

USD in Million2022Weight2023Weight Delta
Discovery and Development of Innovative Drug
100.0 %
10 100.0 % 10 100.0 % -1.37%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
10 100.0 % 10 100.0 % -1.37%

Managers

Managers TitleAgeSince
Chief Executive Officer 57 16-03-28
Director of Finance/CFO 52 22-07-25
Chief Tech/Sci/R&D Officer - 22-01-02
Chief Tech/Sci/R&D Officer - 19-08-12
Chief Tech/Sci/R&D Officer 61 11-08-31
Chief Tech/Sci/R&D Officer 65 01-02-28
Human Resources Officer - 03-12-31
Corporate Officer/Principal - 21-01-02
General Counsel - 02-12-31
Corporate Officer/Principal 59 23-04-30

Members of the board

Members of the board TitleAgeSince
Director/Board Member 71 03-10-31
Chairman 82 00-02-13
Chief Executive Officer 57 16-03-28
Director/Board Member 69 10-06-02
Chief Tech/Sci/R&D Officer 61 11-08-31
Director/Board Member 56 -
Director/Board Member 64 21-12-01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 5,894,085 5,879,121 ( 99.75 %) 0 99.75 %

Shareholders

NameEquities%Valuation
Maverick Capital Ltd.
9.879 %
582,273 9.879 % 6 M $
M28 Capital Management LP
7.159 %
421,951 7.159 % 4 M $
Kingdon Capital Management LLC
4.821 %
284,150 4.821 % 3 M $
Vanguard Global Advisers LLC
3.537 %
208,476 3.537 % 2 M $
Artal Group SA
1.781 %
105,000 1.781 % 1 M $
Citigroup Global Markets, Inc. (Investment Management)
1.559 %
91,872 1.559 % 936 176 $
Renaissance Technologies LLC
1.530 %
90,163 1.530 % 918 761 $
Geode Capital Management LLC
1.063 %
62,682 1.063 % 638 730 $
BlackRock Institutional Trust Co. NA
0.9074 %
53,484 0.9074 % 545 002 $
CM Management LLC
0.4242 %
25,000 0.4242 % 254 750 $

Company contact information

Curis, Inc.

Building C 128 Spring Street

02421, Lexington

+617 503 6500

http://www.curis.com
address Curis, Inc.(CRIS)